Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule

Milestone Pharmaceuticals (MIST) granted equity awards, in the form of a total of 419,000 options to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan, previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees. The Options have a grant date of February 2, 2026, and an exercise price of $1.96 per share, which is equal to the closing price of Milestone’s common shares on the grant date. The shares subject to the Options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.